지역사회획득 폐렴의 치료지침 권고안

키워드

참고문헌 (117)

1. Korea National Statistical Office, "Annual report on the cause of death statistics 2007:Nation Wide" (2007), Korea National Statistical Office
2. Marrie TJ, "Community- Acquired Pneumonia Intervention Trial Assessing Levofloxacin", JAMA, 283, pp.749~755 (2000)
3. Waterer GW, "The influence of the severity of community-acquired pneumonia on the usefulness of blood cultures", Respir Med, 95, pp.78~82 (2001)
4. Mandell LA, "Infectious Diseases Society of America; American Thoracic Society. Infectious Diseases Society of America", American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults, 2007, pp.2, S27~72
5. Jefferson H, "Transportation delay and the microbiological quality of clinical specimens", Am J Clin Pathol, 64, pp.689~693 (1975)
6. Yzerman EP, "Sensitivity of three urinary antigen tests associated with clinical severity in a large outbreak of Legionnaires' disease in The Netherlands", J Clin Microbiol, 40, pp.3232~3236 (2002)
7. Rosn B, "Contribution of a urinary antigen assay (Binax NOW) to the early diagnosis of pneumococcal pneumonia", Clin Infect Dis, 38, pp.222~226 (2004)
8. 김솔잎, "국내 일개 3차 병원에서 양성 NOW™ Legionella 소변 항원 검사의 임상적 의의", The Korean Journal of Laboratory Medicine, 26(2), pp.93~97 (2006), 대한진단검사의학회
9. van der Eerden MM, "Comparison between pathogen directed antibiotic treatment and empirical broad spectrum antibiotic treatment in patients with community acquired pneumonia: a prospective randomised study", Thorax, 60, pp.672~678 (2005)
10. 이재승, "국내 한 3차 병원 중환자실에 입원한 중증지역획득폐렴 환자의 원인 미생물과 경험적 항균제 치료 성적의 고찰", Tuberculosis and Respiratory Diseases, 59(5), pp.522~529 (2005), 대한결핵및호흡기학회
11. Campbell SG, "Ackroyd-Stolarz S. The contribution of blood cultures to the clinical management of adult patients admitted to the hospital with community-acquired pneumonia: a prospective observational study", Chest, 123, pp.1142~1150 (2003)
12. Hahn TH, "The usefulness of quantitative culture of bronchoalveolar lavage fluid in the diagnosis of bacterial pneumonia", Korean J Med, 54, pp.820~826 (1998)
13. Smith MD, "Rapid diagnosis of bacteremic pneumococcal infections in adults by using the Binax NOW Streptococcus pneumoniae urinary antigen test: a prospective, controlled clinical evaluation", J Clin Microbiol, 41, pp.2810~2813 (2003)
14. Murdoch DR, "The NOW S. pneumoniae urinary antigen test positivity rate 6 weeks after pneumonia onset and among patients with COPD", Clin Infect Dis, 37, pp.153~154 (2003)
15. Labarere J, "Comparison of outcomes for low-risk outpatients and inpatients with pneumonia: A propensity-adjusted analysis", Chest, 131, pp.480~488 (2007)
16. Alikhan R, "Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study", Arch Intern Med, 164, pp.963~968 (2004)
17. Minogue MF, "Patients hospitalized after initial outpatient treatment for community-acquired pneumonia", Ann Emerg Med, 31, pp.376~380 (1998)
18. Neill AM, "Community acquired pneumonia: aetiology and usefulness of severity criteria on admission", Thorax, 51, pp.1010~1016 (1996)
19. Labarere J, "Factors associated with the hospitalization of low- risk patients with community-acquired pneumonia in a cluster-randomized trial", J Gen Intern Med, 21, pp.745~752 (2006)
20. 배중훈, "폐렴중증지수를 이용한 폐렴환자의 중증도 분류의 제안", 대한응급의학회지, 13(2), pp.129~134 (2002), 대한응급의학회
21. Choi SO, "Evaluation of risk factors for hospitalization and comparison of empiricregimens for efficacy and toxicity to treat community - acquired pneumonia", J Kor Soc Health-Syst Pharm, 22, pp.36~45 (2005)
22. Bont J, "A prediction rule for elderly primary- care patients with lower respiratory tract infections", Eur Respir J, 29, pp.969~975 (2007)
23. Fine MJ, "The hospital admission decision for patients with community-acquired pneumonia. Results from the pneumonia Patient Outcomes Research Team cohort study", Arch Intern Med, 157, pp.36~44 (1997)
24. Yealy DM, "Effect of increasing the intensity of implementing pneumonia guidelines: a randomized, controlled trial", Ann Intern Med, 143, pp.881~894 (2005)
25. Lim WS, "Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study", Thorax, 58, pp.377~382 (2003)
26. Teramoto S, "Lower respiratory tract infection outcomes are predicted better by an age >80 years than by CURB-65", Eur Respir J, 31, pp.477~478 (2008)
27. Aujesky D, "Prospective comparison of three validated prediction rules for prognosis in community-acquired pneumonia", Am J Med, 118, pp.384~392 (2005)
28. Foley SC, "O'Neill SJ. Audit of the management of patients admitted with community acquired pneumonia", Ir Med J, 99, pp.138~140 (2006)
29. Angus DC, "Severe community-acquired pneumonia: use of intensive care services and evaluation of American and British Thoracic Society Diagnostic criteria", Am J Respir Crit Care Med, 166, pp.717~723 (2002)
30. Ananda-Rajah MR, "Comparing the pneumonia severity index with CURB-65 in patients admitted with community acquired pneumonia", Scand J Infect Dis, 40, pp.293~300 (2008)
31. Marrie TJ, "Admission is not always necessary for patients with community-acquired pneumonia in risk classes IV and V diagnosed in the emergency room", Can Respir J, 14, pp.212~216 (2007)
32. Valencia M, "Pneumonia severity index class v patients with community-acquired pneumonia: characteristics, outcomes, and value of severity scores", Chest, 132, pp.515~522 (2007)
33. Ewig S, "Severe community-acquired pneumonia. Assessment of severity criteria", Am J Respir Crit Care Med, 158, pp.1102~1108 (1998)
34. Ramirez JA, "Switch therapy in community-acquired pneumonia", Diagn Microbiol Infect Dis, 22, pp.219~223 (1995)
35. Ramirez JA, "Early switch from intravenous to oral antibiotics and early hospital discharge: a prospective observational study of 200 consecutive patients with community-acquired pneumonia", Arch Intern Med, 159, pp.2449~2454 (1999)
36. Ramirez JA, "Early switch from intravenous to oral antibiotics in hospitalized patients with bacteremic community-acquired Streptococcus pneumoniae pneumonia", Arch Intern Med, 161, pp.848~850 (2001)
37. Castro-Guardiola A, "Efficacy and safety of oral and early- switch therapy for community-acquired pneumonia: a randomized controlled trial", Am J Med, 111, pp.367~374 (2001)
38. Rhew DC, "A prospective, multicenter study of a pneumonia practice guideline", Chest, 114, pp.115~119 (1998)
39. Halm EA, "Instability on hospital discharge and the risk of adverse outcomes in patients with pneumonia", Arch Intern Med, 162, pp.1278~1284 (2002)
40. Capelastegui A, "Pneumonia: criteria for patient instability on hospital discharge", Chest, 134, pp.595~600 (2008)
41. Halm EA, "Time to clinical stability in patients hospitalized with community-acquired pneumonia: implications for practice guidelines", JAMA, 279, pp.1452~1457 (1998)
42. Jasti H, "Causes and risk factors for rehospitalization of patients hospitalized with community-acquired pneumonia", Clin Infect Dis, 46, pp.550~556 (2008)
43. El Moussaoui R, "Long-term symptom recovery and health-related quality of life in patients with mild-to-moderate-severe community-acquired pneumonia", Chest, 130, pp.1165~1172 (2006)
44. Chang J, "Community acquired pneumonia", Korean J Med, 58, pp.129~144 (2000)
45. Hyun I, "Treatment of Outpatient community-acquired pneumonia", Korean J Med, 64, pp.139~143 (2003)
46. Bruns AH, "Usefulness of consecutive C-reactive protein measurements in follow-up of severe community-acquired pneumonia", Eur Respir J, 32, pp.726~732 (2008)
47. Siegel RE, "antibiotics for community-acquired pneumonia", Chest, 110, pp.965~971 (1996)
48. Lophonte P, "Gemifloxacin once daily for 7 days compared to amoxicillin", clavulanic acid thrice daily for 10 days for the treatment of community-acquired pneumonia of suspected pneumococcal origin, 2004, pp.98, 708~720
49. Rovira E, "Treatment of community- acquired pneumonia in outpatients: randomized study of clarithromycin alone versus clarithromycin and cefuroxime", Respiration, 66, pp.413~418 (1999)
50. Omidvari K, "Early transition to oral antibiotic therapy for community-acquired pneumonia: duration of therapy, clinical outcomes, and cost analysis", Respir Med, 92, pp.1032~1039 (1998)
51. O'Doherty B, "Randomized, double-blind, comparative study of grepafloxacin and amoxicillin in the treatment of patients with community-acquired pneumonia", J Antimicrob Chemother, 40, pp.73~81 (1997)
52. Bruns AH, "Patterns of resolution of chest radiograph abnormalities in adults hospitalized with severe community-acquired pneumonia", Clin Infect Dis, 45, pp.983~991 (2007)
53. Woo JH, "A prospective multicenter study of community-acquired pneumonia in adults with emphasis on bacterial etiology", Korean J Infect Dis, 33, pp.1~7 (2001)
54. Chung MH, "Etiology of community- acquired pneumonia surveyed by 7 university hospitals", Korean J Infect Dis, 29, pp.339~359 (1997)
55. Yu CW, "Clinical features and prognosisof community-acquired pneumonia in the elderly patients", Korean J Infect Dis, 32, pp.212~218 (2000)
56. Sohn JW, "Atypical pathogens as etiologic agents in hospitalized patients with community-acquired pneumonia in Korea: a prospective multi-center study", J Korean Med Sci, 21, pp.602~607 (2006)
57. Song JH, "Epidemiology and clinical outcomes of community-acquired pneumonia in adult patients in Asian countries: a prospective study by the Asian network for surveillance of resistant pathogens", Int J Antimicrob Agents, 31, pp.107~114 (2008)
58. 이대동, "지역사회획득 폐렴에서 레지오넬라 감염의 빈도", The Korean Journal of Laboratory Medicine, 25(6), pp.416~420 (2005), 대한진단검사의학회
59. Joo CH, "A prospective multicenter study on the etiological analysis of community-acquired pneumonia in adult patients in korea: detection of mycoplasma pneumoniae and chlamydia pneumoniae Infections", Korean J Infect Dis, 33, pp.15~24 (2001)
60. Kim MJ, "A prospective multicenter study of the etiological analysis in adults with community- acquired pneumonia: Legionella, Leptospira, Hantaan virus and orientia tsutsugamushi", Korean J Infect Dis, 33, pp.24~31 (2001)
61. Song HS, "The etiological role of legionella pneumophila in patients with community-acquired pneumonia in korea", Tuberc Respir Dis, 50, pp.409~414 (2001)
62. Lee SJ, "Atypical pathogens in adult patients admitted with community-acquired pneumonia in Korea", Jpn J Infect Dis, 55, pp.157~159 (2002)
63. Kim JH, "Viral etiology of community-acquired pneumonia in Korean Adults", Korean J Infect Dis, 33, pp.8~14 (2001)
64. Lew WJ, "An Internet-based surveillance system for tuberculosis in Korea", Int J Tuberc Lung Dis, 10, pp.1241~1247 (2006)
65. 이승헌, "결핵성 폐렴환자의 임상적 고찰", Tuberculosis and Respiratory Diseases, 57(1), pp.19~24 (2004), 대한결핵및호흡기학회
66. 박상돈, "여름에 비정형 폐렴으로 발현한 쯔쯔가무시병 1예", Infection and Chemotherapy, 40(4), pp.241~245 (2008), 대한감염학회
67. Kim BN, "Risk factors for penicillin resistance and mortality in Korean adults with Streptococcus pneumoniae bacteremia", Eur J Clin Microbiol Infect Dis, 21, pp.35~42 (2002)
68. Lee NY, "Carriage of antibiotic-resistant pneumococci among Asian children: a multinational surveillance by the Asian Network for Surveillance of Resistant Pathogens (ANSORP)", Clin Infect Dis, 32, pp.1463~1469 (2001)
69. Farrell DJ, "Molecular characterization of macrolide resistance mechanisms among Streptococcus pneumoniae and Streptococcus pyogenes isolated from the PROTEKT 1999-2000 study", J Antimicrob Chemother 50 Suppl, S1, pp.39~47 (2002)
70. Schito GC, "Susceptibility of Streptococcus pneumoniae to penicillin, azithromycin and telithromycin (PROTEKT 1999-2003)", Int J Antimicrob Agents, 26, pp.479~485 (2005)
71. Song JH, "High prevalence of antimicrobial resistance among clinical Streptococcus pneumoniae isolates in Asia (an ANSORP study)", Antimicrob Agents Chemother, 48, pp.2101~2107 (2004)
72. 이경원, "High Prevalence of Ceftazidime-Resistant Klebsiella pneumoniae and Increase of Imipenem-Resistant", Yonsei Medical Journal, 47(5), pp.634~645 (2006), 연세대학교의과대학
73. Shin JH, "Prevalence, characteristics, and molecular epidemiology of macrolide and fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae at five tertiary-care hospitals in Korea", Antimicrob Agents Chemother, 51, pp.2625~2627 (2007)
74. Kim IS, "Diversity of ampicillin resistance genes and antimicrobial susceptibility patterns in Haemophilus influenzae strains isolated in Korea", Antimicrob Agents Chemother, 51, pp.453~460 (2007)
75. 장명웅, "Mycoplasma pneumoniae의 신속 동정과 분리균의 항생제 감수성 검사", Journal of Bacteriology and Virology, 33(3), pp.183~191 (2003), 대한미생물학회
76. Morozumi M, "Acute Respiratory Diseases Study Group. Increased macrolide resistance of Mycoplasma pneumoniae in pediatric patients with community-acquired pneumonia", Antimicrob Agents Chemother, 52, pp.348~350 (2008)
77. Arnold FW, "A worldwide perspective of atypical pathogens in community-acquired pneumonia", J Respir Crit Care Med, 175, pp.1086~1093 (2007)
78. Robenshtok E, "Empiric antibiotic coverage of atypical pathogens for community acquired pneumonia in hospitalized adults", Cochrane Database Syst Rev, pp.CD004418~ (2008)
79. Pichichero ME, "A review of evidence supporting the American Academy of Pediatrics recommendation for prescribing cephalosporin antibiotics for penicillin- allergic patients", Pediatrics, 115, pp.1048~1057 (2005)
80. Granizo JJ, "GiThe efficacy of cefditoren pivoxil in the treatment of lower respiratory tract infections, with a focus on the per-pathogen bacteriologic response in infections caused by Streptococcus pneumoniae and Haemophilus influenzae: a pooled analysis of seven clinical trials", Clin Ther, 28, pp.2061~2069 (2006)
81. Lee MY, "In vitro activity of cefditoren: antimicrobial efficacy against major respiratory pathogens from Asian countries", Int J Antimicrob Agents, 28, pp.14~18 (2006)
82. 이종윤, "경구용 세팔로스포린계 항생제 Cefditoren pivoxil의 주요 임상분리세균에 대한 시험관내 항균력", Infection and Chemotherapy, 35(4), pp.211~214 (2003), 대한감염학회
83. Heffelfinger JD, "Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group", Arch Intern Med, 160, pp.1399~1408 (2000)
84. Lautenbach E, "Fluoroquinolone utilization in the emergency departments of academic medical centers: prevalence of, and risk factors for, inappropriate use", Arch Intern Med, 163, pp.601~605 (2003)
85. Noreddin AM, "Pharmacodynamic target attainment analysis against Streptococcus pneumoniae using levofloxacin 500 mg, 750 mg and 1000 mg once daily in plasma (P) and epithelial lining fluid (ELF) of hospitalized patients with community acquired pneumonia (CAP)", Int J Antimicrob Agents, 24, pp.479~484 (2004)
86. File TM Jr, "Clinical implications of 750 mg, 5-day levofloxacin for the treatment of community-acquired pneumonia", Curr Med Res Opin, 20, pp.1473~1481 (2004)
87. File TM Jr, "Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study", J Antimicrob Chemother, 60, pp.112~120 (2007)
88. Gleason PP, "Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia", Arch Intern Med, 159, pp.2562~2572 (1999)
89. Dudas V, "Antimicrobial selection for hospitalized patients with presumed community-acquired pneumonia: a survey of nonteaching US community hospitals", Ann Pharmacother, 34, pp.446~452 (2000)
90. Brown RB, "Impact of initial antibiotic choice on clinical outcomes in community-acquired pneumonia: analysis of a hospital claims-made database", Chest, 123, pp.1503~1511 (2003)
91. Mufson MA, "Penicillin resistance not a factor in outcome from invasive Streptococcus pneumoniae community-acquired pneumonia in adults when appropriate empiric therapy is started", Am J Med Sci, 333, pp.161~167 (2007)
92. Cardoso MR, "Penicillin-resistant pneumococcus and risk of treatment failure in pneumonia", Arch Dis Child, 93, pp.221~225 (2008)
93. Song JH, "Asian Network for Surveillance of Resistant Pathogens Study Group. Clinical outcomes of pneumococcal pneumonia caused by antibiotic-resistant strains in asian countries: a study by the Asian Network for Surveillance of Resistant Pathogens", Clin Infect Dis, 38, pp.1570~1578 (2004)
94. 홍지현, "폐렴구균에 의한 지역사회 획득 폐렴에서 페니실린 내성률과 내성에 따른 임상경과에 관한 연구", Tuberculosis and Respiratory Diseases, 54(3), pp.295~303 (2003), 대한결핵및호흡기학회
95. Hwangbo B, "Clinical characteristics of pneumococcal bacteremia in adults: the effect of penicillin resistance on the mortality of patients with pneumococcal bacteremia", Tuberc Respir Dis, 47, pp.184~194 (1999)
96. Torres A, "Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial", Clin Infect Dis, 46, pp.1499~1509 (2008)
97. Bhavnani SM, "Cost-effectiveness of oral gemifloxacin versus intravenous ceftriaxone followed by oral cefuroxime with", without a macrolide for the treatment of hospitalized patients with community-acquired pneumonia, 2008, pp.60, 59~64
98. Shorr AF, "Levofloxacin 750-mg for 5 days for the treatment of hospitalized Fine Risk Class III", IV community-acquired pneumonia patients, 2006, pp.100, 2129~2136
99. Khashab MM, "Comparison of the adverse event profiles of levofloxacin 500 mg and 750 mg in clinical trials for the treatment of respiratory infections", Curr Med Res Opin, 22, pp.1997~2006 (2006)
100. File TM, "Community-acquired pneumonia", Lancet, 362, pp.1991~2001 (2003)
101. Torres A, "Severe community-acquired pneumonia. Epidemiology and prognostic factors", Am Rev Respir Dis, 144, pp.312~318 (1991)
102. Leroy O, "Comparison of levofloxacin and cefotaxime combined with ofloxacin for ICU patients with community-acquired pneumonia who do not require vasopressors", Chest, 128, pp.172~183 (2005)
103. Baddour LM, "International Pneumococcal Study Group. Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal baceremia", Am J Respir Crit Care Med, 170, pp.440~444 (2004)
104. Waterer GW, "Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia", Arch Intern Med, 161, pp.1837~1842 (2001)
105. Arancibia F, "Community-acquired pneumonia due to gram-negative bacteria and pseudomonas aeruginosa: incidence, risk, and prognosis", Arch Intern Med, 162, pp.1849~1858 (2002)
106. Woodhead M, "European Respiratory Society; European Society of Clinical Microbiology and Infectious Diseases. Guidelines for the management of adult lower respiratory tract infections", Eur Respir J, 26, pp.1138~1180 (2005)
107. Committee for The Japanese Respiratory Society guidelines for the management of respiratory infections, "Guidelines for the management of community acquired pneumonia in adults, revised edition", Respirology 11 Suppl, 3, pp.S79~133 (2006)
108. Craig WA, "Pharmacodynamics of antimicrobials: general concepts and applications in Antimicrobial phamacodynamics in theory and clinical practice", pp.1~19 (2007), Informa healthcare
109. Rizzato G, "Efficacy of a three day course of azithromycin in moderately severe community-acquired pneumonia", Eur Respir J, 8, pp.398~402 (1995)
110. Dunbar LM, "High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm", Clin Infect Dis, 37, pp.752~760 (2003)
111. Schnwald S, "Comparison of three- day and five-day courses of azithromycin in the treatment of atypical pneumonia", Eur J Clin Microbiol Infect Dis, 10, pp.877~880 (1991)
112. Menndez R, "Risk factors of treatment failure in community acquired pneumonia: implications for disease outcome", Thorax, 59, pp.960~965 (2004)
113. Arancibia F, "Antimicrobial treatment failures in patients with community- acquired pneumonia: causes and prognostic implications", Am J Respir Crit Care Med, 162, pp.154~160 (2000)
114. Menndez R, "Reaching stability in community-acquired pneumonia: the effects of the severity of disease, treatment, and the characteristics of patients", Clin Infect Dis, 39, pp.1783~1790 (2004)
115. Celis R, "Nosocomial pneumonia. A multivariate analysis of risk and prognosis", Chest, 93, pp.318~324 (1988)
116. Sanyal S, "Initial microbiologic studies did not affect outcome in adults hospitalized with community- acquired pneumonia", Am J Respir Crit Care Med, 160, pp.346~348 (1999)
117. Rosn B, , Arch Intern Med, 164, pp.502~508 (2004)

관련 논문AI추천